Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.63 |
| ▸ | CNR1 | P21554 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908974 | 0.91 | CNR2 (0.62) | CNR2CNR1 | |
| SCHEMBL2187287 | 0.91 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL16161356 | 0.86 | CNR2 (0.65) | CNR2CNR1 | |
| SCHEMBL5110999 | 0.84 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL4731309 | 0.82 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL496092 | 0.81 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL496843 | 0.81 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL16161235 | 0.81 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL11865187 | 0.80 | CCNA2 (0.46) | CNR2CNR1 | |
| SCHEMBL495832 | 0.79 | CNR2 (0.54) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181196-B2 | Pharmaceutical compounds | KEMOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | KEMOTECH S.R.L. (IT) | 2014-11-20 | — | — | US | disclosed |
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | KEMOTECH S.R.L. (IT) | 2014-11-20 | — | — | US | disclosed |
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | KEMOTECH S.R.L. (IT) | 2014-11-20 | — | — | US | disclosed |
| EP-2789619-A1 | Pharmaceutical compounds wiht angiogenesis inbhibitory activity | Kemotech S.r.l. (IT) | 2014-10-15 | — | — | EP | disclosed |
| EP-2789619-A1 | Pharmaceutical compounds wiht angiogenesis inbhibitory activity | Kemotech S.r.l. (IT) | 2014-10-15 | — | — | EP | disclosed |
| US-7384960-B2 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-06-10 | — | — | US | disclosed |
| US-20050192332-A1 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | CYP3A43, CYP2D6, CYP2C9 | CNR2 576/4885CNR1 426/4885 |
| US-20050192332-A1 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | CNR1, CNR2, CBR3 | CNR2 2/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.